Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

VYNE Therapeutics (VYNE) Cash from Operations (2017 - 2025)

VYNE Therapeutics' Cash from Operations history spans 9 years, with the latest figure at 10764000.0 for Q2 2025.

  • For Q2 2025, Cash from Operations fell 26.9% year-over-year to 10764000.0; the TTM value through Jun 2025 reached 39773000.0, down 48.67%, while the annual FY2025 figure was 33124000.0, 2.5% up from the prior year.
  • Cash from Operations reached 10764000.0 in Q2 2025 per VYNE's latest filing, up from 11500000.0 in the prior quarter.
  • In the past five years, Cash from Operations ranged from a high of 4811000.0 in Q4 2022 to a low of 17541000.0 in Q3 2021.
  • Average Cash from Operations over 5 years is 9285777.78, with a median of 8754500.0 recorded in 2024.
  • Peak YoY movement for Cash from Operations: soared 75.96% in 2021, then crashed 74.65% in 2024.
  • A 5-year view of Cash from Operations shows it stood at 10018000.0 in 2021, then surged by 51.98% to 4811000.0 in 2022, then decreased by 6.78% to 5137000.0 in 2023, then tumbled by 74.65% to 8972000.0 in 2024, then fell by 19.97% to 10764000.0 in 2025.
  • Per Business Quant, the three most recent readings for VYNE's Cash from Operations are 10764000.0 (Q2 2025), 11500000.0 (Q1 2025), and 8972000.0 (Q4 2024).